Secura Bio, Inc.
https://securabio.com/
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From Secura Bio, Inc.
Dizal Scores First JAK1 Approval For Advanced PTCL
China's Dizal has won the first approval worldwide, in its home market, for a JAK1 inhibitor in relapsed/refractory peripheral T-cell lymphoma (PTCL), based on a pivotal Phase II trial. The biotech is also planning a Phase III study with the molecule for second-line PTCL.
Yakult Reduces Oncology Portfolio As It Looks Towards Microbiome
The Japanese firm has decided to shrink its oncology portfolio by transferring its rights to oxaliplatin in Japan, along with a portfolio of generics, to Takata. Though Yakult will maintain an interest in the area through irinotecan and several other anticancers, its has said future R&D investment will shift more towards the microbiome.
US FDA Center Directors Should Not Influence Adcomm Votes Or Overrule Scientific Staff, Coalition Says
In a letter to Commissioner Robert Califf, the Patient, Consumer and Public Health Coalition says medical product center directors and other senior staff should refrain from trying to sway advisory committee votes and be reminded that overruling decisions of their own scientific staff undermines the public trust.
Status Quo: US Approvals For Pepaxto, Copiktra Remain Intact Despite Negative Panel Reviews
More than seven months after the Oncologic Drugs Advisory Committee voted that Pepaxto and Copiktra had negative benefit-risk profiles in their labeled indications, the drugs' approvals remain intact. Oncopeptides is still considering whether to heed the FDA's request to withdraw the Pepaxto NDA, even though the drug is not currently marketed. Secura Bio says Copiktra remains on the market and available for prescribing.
Company Information
- Industry
- Biotechnology
- Pharmaceuticals
-
Pharmaceuticals
- Generic Drugs
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice